The Oncology Institute Projects Positive 2026 Adjusted EBITDA, Reports Strong Q4 & Full Year 2025 Results
Summary
The Oncology Institute reported significantly improved financial results for Q4 and full year 2025, highlighted by a positive Adjusted EBITDA of $147 thousand in Q4, a substantial improvement from a $(7.8) million loss in the prior year. For the full year 2025, the company reduced its Adjusted EBITDA loss to $(12.4) million from $(35.7) million in 2024, alongside a 27.8% revenue increase to $502.7 million. Critically, TOI issued strong guidance for 2026, projecting revenue between $630 million and $650 million and, most notably, a positive Adjusted EBITDA ranging from $0 to $9 million. This anticipated shift to profitability, driven by continued expansion of its capitated care model, represents a material positive development for the company and could significantly impact its valuation. Investors will closely watch the company's execution against these targets, especially the achievement of sustained positive Adjusted EBITDA.
At the time of this announcement, TOI was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $257.8M. The 52-week trading range was $0.63 to $4.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.